These are all aliases for one guy I would imagine. Someone who is desperately underwater on a short.
If the overall stock market is a monster bubble, then why focus on one stock to short?
Why not short the whole market using a basket of stocks, such as a whole market ETF, and remove idiosyncratic risk?
Anything AMZN sells (except maybe the Kindle) I can buy somewhere else. Not much of a monopoly.
And now your short is even further underwater.
Better PE (current and forward) and better Price-to-Book ratio than AMZN. What on your thoughts on AMZN? I'd think by your logic that AMZN would be a better short.
You probably don't even know what a Ponzi scheme is.
"Back to 60?" it wasn't at 60.
How far underwater is your short?
You'd have done better to buy CTRP on the open. It has continued up, this has fallen.
What catalyst would you be looking for after a 100% survival rate and no adverse side effect? 110% survival with a free pony?
The only reason that it would be a learning lesson is because he got it wrong. He's talking like he got it wrong (which he did) and is trying to figure out why. That makes it a learning lesson.
You must have missed the numerous articles pointing out that the Chinese are now the biggest spending international travelers. Google is your friend. Try "China overtakes US as number one spender on international travel" and check out the search results.
No valid comparison exists between Puma (PBYI) and BIIB.
Some sample data:
Market Capitalization BIIB $91.7B PBYI $6.7B
Earnings per Share (TTM) BIIB $13.86 PBYI ($5.71)
Total Revenue (TTM) BIIB $10.1B PBYI N/A
Employees (Full Time) BIIB 7,550 PBYI 120
Do you have any data that would make such a comparison valid?
It's a little absurd at this point. Balance sheet, cash flow and earnings are all strong and improving.
So you can't contest any of the facts I wrote, and you will not even try?
Just as I thought. Share price moves up and down for a lot of reasons.
Can you contest any of the facts that I wrote? Until you can, you're just blowing wind.
Flat earnings this quarter is due to a one-time special item in the prior year period, as noted in the the news coverage of the report:: "Earnings per share was $0.63 (adjusted for the Company’s four-for-one class A common stock split on March 19, 2015), flat over the prior year period and reflective of the one-time favorable tax benefit of $201 million recognized in that period."
They beat estimates, grew earnings and revenue in an unfavorable currency environment, and have solid prospects with Costco and China, and other ventures, going forward.
Now it's down a bit after hours. After hours does not mean much, unless you see a big move and strong volume. Give everyone time to digest the earnings report. All in all, things look pretty good.
Up after hours, so far.
I don't think people are in Visa for the dividend.
In the press release, it says "In the study, the primary endpoint comparison of MYDICAR to placebo resulted in a hazard ratio of 0.93"
A hazard ratio of 1 (100%) would correspond to exactly the same as placebo. A hazard ratio of 0.93 (93%) correspond to a 7% improvement (100% - 93%). In the Adam Feuerstein article, he says 6% to 7% (probably assuming that the actual hazard ratio is 0.93 and a fraction).